The backtest results show that AZN has a strong positive response following earnings beats, with a 72.73% win rate over 3 days, increasing to 90.91% over 30 days, and an average 30-day return of 3.25%. This indicates a consistent upward trend in AZN's stock price after earnings surprises. The analysis suggests that the stock tends to gain steadily, peaking around day 16. Investors may find value in holding AZN shares for up to a month post-earnings beat to maximize returns.

backtest_data

The backtest results show that AZN has a low short-term win rate of 33.33% within 3 days after missing earnings expectations, but the win rate improves to 66.67% at 10 days and reaches 100% at 30 days. The 3-day return is negative at -1.74%, while the 10-day and 30-day returns turn positive, with a 3.78% gain at 30 days. This suggests that although AZN initially reacts negatively, it tends to recover and generate positive returns over the longer term.

This pattern indicates that investors might consider holding AZN for at least 30 days following an earnings miss to capture potential recovery gains.

Therefore, a longer-term investment horizon post-earnings miss could be beneficial for AZN shareholders.

The backtest results reveal that the Pharmaceuticals Industry experienced a slight negative impact, with a maximum return of -0.37% on the event day following earnings beats. This suggests that despite positive earnings surprises, the industry did not gain immediate price appreciation during the tested period.

The analysis indicates that earnings beats in this sector may not translate into short-term stock price gains, possibly due to market expectations or other overriding factors.

Investors should be cautious about expecting immediate positive returns from earnings beats in the Pharmaceuticals Industry and consider longer-term or alternative signals.

The backtest results reveal that the Pharmaceuticals Industry experiences a negative impact following earnings misses, with a maximum return decline of 0.50% on the event day. This consistent negative reaction across 541 events indicates a modest but immediate adverse market response. The analysis suggests that earnings misses in this sector tend to trigger short-term price declines, reflecting investor sensitivity to underperformance. Investors should consider the potential downside risk when pharmaceutical companies report earnings below expectations, possibly adopting cautious or defensive strategies around such announcements.

Backtest AZN Release Earning Report

Find all upcoming company earnings reports scheduled for feb 10 2026. Get details on which companies are reporting and their expected results.

Calendario